Related Experiment Video
Updated: Mar 2, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.8K
Pharmacotherapy options for pediatric diabetes.
Maria Loredana Marcovecchio1, Francesco Chiarelli
1aDepartment of Paediatrics, University of Cambridge, Cambridge, UK bDepartment of Paediatrics, University of Chieti, Chieti, Italy.
Current Opinion in Pediatrics
|May 17, 2017
Summary
Current treatments for pediatric type 1 diabetes (T1D) and type 2 diabetes (T2D) include insulin and metformin, respectively. Advances in technology and new drug development are crucial for improving glycemic control in youth.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Type 1 diabetes (T1D) and type 2 diabetes (T2D) are increasingly prevalent in children and adolescents.
- Effective management strategies are essential for long-term health outcomes in pediatric diabetes patients.
Purpose of the Study:
- To provide an updated review of current treatment strategies for T1D and T2D in children and adolescents.
- To highlight approved therapeutic options and emerging advancements in pediatric diabetes care.
Main Methods:
- Review of current literature on T1D and T2D treatments approved for pediatric use.
- Analysis of technological advancements and pharmacological developments in diabetes management.
Main Results:
- Insulin therapy remains the cornerstone for pediatric T1D management, with ongoing development of advanced insulin analogues.
- Technological innovations like insulin pump therapy, continuous glucose monitoring, and artificial pancreas systems are transforming T1D care.
- Lifestyle interventions and metformin are first-line treatments for pediatric T2D, with limited evidence for other oral agents.
Conclusions:
- Significant progress has been made, but achieving physiological insulin coverage remains a key challenge for T1D.
- There is a critical need for novel pharmacotherapies for both T1D and T2D to improve glycemic control in pediatric populations.
- Further research is required to expand treatment options for adolescents with difficult-to-manage diabetes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
293
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
340
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
340
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
411
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
411
01:29Drug Dosing: Infants and Children
457
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
457
01:16Insulin: Dosing Regimen and Adverse Effects
952
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
952